HUP0004170A2 - Eljárás és anyagok nyálkaszövetek gyulladásának kezelésére és megelőzésére - Google Patents

Eljárás és anyagok nyálkaszövetek gyulladásának kezelésére és megelőzésére

Info

Publication number
HUP0004170A2
HUP0004170A2 HU0004170A HUP0004170A HUP0004170A2 HU P0004170 A2 HUP0004170 A2 HU P0004170A2 HU 0004170 A HU0004170 A HU 0004170A HU P0004170 A HUP0004170 A HU P0004170A HU P0004170 A2 HUP0004170 A2 HU P0004170A2
Authority
HU
Hungary
Prior art keywords
materials
induced
fungi
methods
prevention
Prior art date
Application number
HU0004170A
Other languages
English (en)
Inventor
Jens Ponikau
Original Assignee
Jens Ponikau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jens Ponikau filed Critical Jens Ponikau
Publication of HUP0004170A2 publication Critical patent/HUP0004170A2/hu
Publication of HUP0004170A3 publication Critical patent/HUP0004170A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)

Abstract

InterLn=1386;>(57) A találmány eljárásokkal és anyagokkal foglalkoziknem terjedő gombák által indukált mukozitisz kezelésére ésmegelőzésére. Pontosabban a találmány gombaellenes szerek beadásávalfoglalkozik úgy, hogy ezek érintkezésbe lépjenek a nyálkával olyanmennyiségben, gyakorisággal és időtartamon át, amely hatékony a nemterjedő gomba által indukált rinoszinuszitisz megelőzésére,csökkentésére vagy eltüntetésére. A találmány eljárásokat és anyagokatis nyújt nem terjedő gomba által indukált rinoszinuszitiszdiagnosztizálására és nem terjedő gombák kitenyésztésére emlősöknyálka mintáiból, továbbá speciális gombaellenes kiszereléseket ésorvosi berendezéseket nyújt nem terjedő gomba által indukáltrinoszinuszitisz kezelésére és megelőzésére. A találmány továbbáeljárásokat és anyagokat biztosít más nem-terjedő gomba által indukáltmukozitiszes állapotok kezelésére és megelőzésére is, ilyenek példáula krónikus középfülgyulladás, krónikus vastagbélgyulladás és Crohn-féle betegség. A találmány továbbá eljárásokat és anyagokat biztosít akrónikus asztma tüneteinek kezelésére és megelőzésére. Ó
HU0004170A 1997-10-22 1998-10-22 Methods and materials for treating and preventing inflammation ofmucosal tissue HUP0004170A3 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US6270997P 1997-10-22 1997-10-22
US6341497P 1997-10-28 1997-10-28
US6341897P 1997-10-28 1997-10-28
US8327298P 1998-04-28 1998-04-28
US8639798P 1998-05-22 1998-05-22
PCT/US1998/022403 WO1999020261A2 (en) 1997-10-22 1998-10-22 Use of antigunal agents for the topial treatment of fungus-induced mucositis

Publications (2)

Publication Number Publication Date
HUP0004170A2 true HUP0004170A2 (hu) 2001-05-28
HUP0004170A3 HUP0004170A3 (en) 2001-12-28

Family

ID=27535591

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004170A HUP0004170A3 (en) 1997-10-22 1998-10-22 Methods and materials for treating and preventing inflammation ofmucosal tissue

Country Status (28)

Country Link
US (9) US6291500B2 (hu)
EP (2) EP1024814B1 (hu)
JP (3) JP2001520188A (hu)
KR (4) KR20010031363A (hu)
CN (1) CN1143679C (hu)
AP (1) AP2000001805A0 (hu)
AT (1) ATE371457T1 (hu)
AU (1) AU1195999A (hu)
BG (1) BG104371A (hu)
BR (1) BR9814615A (hu)
CA (1) CA2308201C (hu)
DE (1) DE69838338T2 (hu)
DK (1) DK1024814T3 (hu)
EA (1) EA200000439A1 (hu)
EE (1) EE200000253A (hu)
ES (1) ES2292210T3 (hu)
HK (1) HK1029935A1 (hu)
HU (1) HUP0004170A3 (hu)
ID (1) ID26104A (hu)
IL (2) IL135774A0 (hu)
IS (1) IS5463A (hu)
NO (1) NO325714B1 (hu)
OA (1) OA11351A (hu)
PL (1) PL340606A1 (hu)
PT (1) PT1024814E (hu)
SK (1) SK5732000A3 (hu)
TR (1) TR200001117T2 (hu)
WO (1) WO1999020261A2 (hu)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045815A (en) * 1997-08-15 2000-04-04 Board Of Regents, The University Of Texas System Parenteral pimaricin as treatment of systemic infections
US6844004B2 (en) 1997-08-15 2005-01-18 Board Of Regents, The University Of Texas System Topical formulations of natamycin/pimaricin
PT1024814E (pt) * 1997-10-22 2007-11-29 Mayo Foundation Utilização de agentes antifúngicos para o tratamento tópico de mucosite induzida por fungo
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
AU5975700A (en) * 1999-07-02 2001-01-22 Janssen Pharmaceutica N.V. Nasal formulation of an antifungal
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
SE521431C2 (sv) * 1999-12-02 2003-11-04 Sca Hygiene Prod Ab Användning av en pH-buffrande substans för att förhindra hudinfektioner orsakade av Candida Albicans
AU2001232787A1 (en) * 2000-01-14 2001-07-24 University Of Virginia Patent Foundation Airway alkalinization as therapy for airway diseases
AU2001236448A1 (en) * 2000-02-18 2001-08-27 Eli Lilly And Company Methods of treatment for non-invasive fungus-induced mucositis with cyclohexapeptide antifungal agents
US7150888B1 (en) 2000-04-03 2006-12-19 Inhalation, Inc. Methods and apparatus to prevent colds, influenzaes, tuberculosis and opportunistic infections of the human respiratory system
US7048953B2 (en) * 2000-04-03 2006-05-23 Inhalation, Inc. Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute respiratory syndrome (SARS)
US8404217B2 (en) * 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US6767537B2 (en) 2000-05-26 2004-07-27 Phil Arnold Nicolay Composition and method for the treatment of sinusitis
WO2002007682A1 (en) * 2000-07-26 2002-01-31 Vyden John K Methods for treating atopic disorders
EP1239853B1 (de) * 2000-09-14 2006-11-08 Waldemar Gottardi Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
JP4822652B2 (ja) * 2000-11-22 2011-11-24 エンド ファーマシューティカルズ インコーポレイテッド 粘膜炎の治療
JP2004517127A (ja) 2000-12-21 2004-06-10 ネクター セラピューティックス ポリエン抗真菌剤の肺送達
US7770577B2 (en) * 2001-05-15 2010-08-10 Gregory E Conner Methods and devices for treating lung dysfunction
JPWO2002098463A1 (ja) * 2001-06-05 2004-09-16 財団法人新産業創造研究機構 抗真菌組成物
US7244703B2 (en) * 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
AUPS017702A0 (en) * 2002-01-25 2002-02-14 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders
US20040019316A1 (en) * 2002-03-13 2004-01-29 Morris John K. Nasal airway delivery, decongestion system (NADDS)
AU2003259028A1 (en) * 2002-06-10 2003-12-22 Combinatorx, Incorporated Combinations for the treatment of rheumatoid arthritis
WO2004000272A1 (en) * 2002-06-20 2003-12-31 Novartis Consumer Health S.A. Nasal compositions comprising a mucopolysaccharide and propylene glycol
US20050032896A1 (en) * 2002-06-21 2005-02-10 Liisa Neumann Use of synthetic retinoic acid in form of 13-cis vitamin A for treatment of autism
WO2004004700A1 (en) * 2002-07-02 2004-01-15 Novartis Ag Methods for the treatment of sinusitis
US20040029893A1 (en) * 2002-07-23 2004-02-12 Lane Edward M. Method of treatment of non-invasive mucositis
ES2494791T3 (es) 2002-09-18 2014-09-16 Trustees Of The University Of Pennsylvania Uso de rapamicina para el tratamiento o prevención de la degeneración macular asociada a la edad
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
WO2004110346A2 (en) * 2002-10-29 2004-12-23 Transave, Inc. Sustained release of antiinfectives
WO2005000195A2 (en) * 2002-11-13 2005-01-06 Rosenberg Yvonne J A pretreatment or post exposure treatment for exposure to a toxic substance by pulmonary delivery (inhaler) of a bioscavenger
US6890323B1 (en) * 2002-12-03 2005-05-10 University Of Florida Small volume effusion trap
CA2511555A1 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Aerosolizable pharmaceutical formulation for fungal infection therapy
US7544192B2 (en) 2003-03-14 2009-06-09 Sinexus, Inc. Sinus delivery of sustained release therapeutics
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US20050043251A1 (en) * 2003-08-20 2005-02-24 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
US20070078116A1 (en) * 2003-08-20 2007-04-05 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
US20050159369A1 (en) * 2003-08-20 2005-07-21 Qtm Llc Method of treatment of otitis externa
US7749509B2 (en) * 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US7731976B2 (en) * 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US20060177424A1 (en) * 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US7759105B2 (en) * 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US8192733B2 (en) * 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20050058673A1 (en) * 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
WO2005022998A2 (en) * 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
EP1672989B1 (en) * 2003-09-09 2012-04-25 3M Innovative Properties Company Concentrated antimicrobial compositions and methods
CA2538991A1 (en) 2003-09-18 2005-03-31 Children's Medical Center Corporation Treatment of severe distal colitis
KR100978717B1 (ko) 2003-12-08 2010-08-30 씨펙스 파마슈티칼스, 인코포레이티드 인슐린 치료를 위한 약제 조성물 및 방법
US8741332B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for dermally treating neuropathic pain
US20080019927A1 (en) * 2004-06-07 2008-01-24 Jie Zhang Compositions and methods for dermally treating neuropathy with minoxidil
US20070196293A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Compositions and methods for treating photo damaged skin
US20070189978A1 (en) * 2004-06-07 2007-08-16 Jie Zhang Compositions and methods for dermally treating musculoskeletal pain
US20070196325A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Compositions and methods for dermally treating infections
US8741333B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
US20070196453A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs
US20070196457A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more volatile solvent-containing compositions and methods for dermal delivery of drugs
US8907153B2 (en) 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
US20070190124A1 (en) * 2004-06-07 2007-08-16 Jie Zhang Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs
US20070196452A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
US20060009424A1 (en) * 2004-07-06 2006-01-12 Anatoly Kogan Nasaleaze
MY145148A (en) * 2004-08-13 2011-12-30 Schering Plough Ltd Pharmaceutical formulation comprising an antibiotic, a triazole and a carticosteroid
US9028852B2 (en) * 2004-09-07 2015-05-12 3M Innovative Properties Company Cationic antiseptic compositions and methods of use
US8198326B2 (en) * 2004-09-07 2012-06-12 3M Innovative Properties Company Phenolic antiseptic compositions and methods of use
US20060051384A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Antiseptic compositions and methods of use
KR100675379B1 (ko) * 2005-01-25 2007-01-29 삼성전자주식회사 프린팅 시스템 및 프린팅 방법
US8109981B2 (en) 2005-01-25 2012-02-07 Valam Corporation Optical therapies and devices
BRPI0608152A2 (pt) 2005-02-09 2009-11-10 Macusight Inc formulações para tratamento ocular
US20060229364A1 (en) * 2005-03-10 2006-10-12 3M Innovative Properties Company Antiviral compositions and methods of use
US10918618B2 (en) * 2005-03-10 2021-02-16 3M Innovative Properties Company Methods of reducing microbial contamination
CA2598985A1 (en) * 2005-03-10 2006-09-21 3M Innovative Properties Company Antimicrobial pet wipes and methods
CN101137359B (zh) * 2005-03-10 2011-01-12 3M创新有限公司 治疗耳感染的方法
AU2006223136A1 (en) * 2005-03-10 2006-09-21 3M Innovative Properties Company Antimicrobial compositions comprising esters of hydroxycarboxylic acids
US8025635B2 (en) 2005-04-04 2011-09-27 Intersect Ent, Inc. Device and methods for treating paranasal sinus conditions
US7670849B2 (en) * 2005-04-29 2010-03-02 Henkin Robert I Method for diagnosing insulin resistance from nasal secretions
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
WO2007038466A2 (en) * 2005-09-27 2007-04-05 Cobb & Company Treatment of bipolar disorder utilizing anti-fungal compositions
ITRM20050561A1 (it) * 2005-11-10 2007-05-11 D M G Italia S R L Soluzione otologica e metodo per la sua preparazione.
AU2006320538B2 (en) * 2005-11-30 2013-07-04 Endo Pharmaceuticals Inc. Treatment of xerostomia with a sulfur-containing antioxidant
PT1962805T (pt) 2005-12-08 2016-10-05 Insmed Inc Composições de anti-infeciosos baseadas em lípidos para tratamento de infeções pulmonares
US20070226012A1 (en) * 2005-12-13 2007-09-27 Naryx Pharma, Inc. Methods of measuring symptoms of chronic rhinosinusitis
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
US20070219600A1 (en) * 2006-03-17 2007-09-20 Michael Gertner Devices and methods for targeted nasal phototherapy
JP5506378B2 (ja) 2006-03-23 2014-05-28 参天製薬株式会社 血管透過性に関連する疾患または病気のための製剤および方法
US20100190735A1 (en) * 2006-03-28 2010-07-29 Myrex Pharmaceuticals Inc. Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis
WO2007117550A2 (en) * 2006-04-06 2007-10-18 Transave, Inc. Methods for coacervation induced liposomal encapsulation and formulations thereof
US20070280972A1 (en) * 2006-04-25 2007-12-06 Zars, Inc. Adhesive solid gel-forming formulations for dermal drug delivery
US20070286812A1 (en) * 2006-06-09 2007-12-13 Toutounghi Camille Nasal formulation
US20070286813A1 (en) * 2006-06-09 2007-12-13 Toutounghi Camille Nasal formulation
US8535707B2 (en) 2006-07-10 2013-09-17 Intersect Ent, Inc. Devices and methods for delivering active agents to the osteomeatal complex
US20080131420A1 (en) * 2006-07-13 2008-06-05 Accentia, Inc. Methods and compositions for treating mucosal inflammation
US20080075793A1 (en) * 2006-09-21 2008-03-27 Dunshee Wayne K Antiviral compositions and methods of use
US20080107723A1 (en) * 2006-09-28 2008-05-08 Perkins Walter R Methods of Treating Pulmonary Distress
EP2079306A4 (en) * 2006-10-03 2009-12-30 Accentia Biopharmaceuticals In NON-MOLECULE-BREAKING AMPHOTERICIN B FORMULATIONS AND METHOD FOR TREATING NON-INVASIVE PULSE-INDUCED MUCOSITIS
CN101489379B (zh) 2006-10-27 2014-06-04 3M创新有限公司 抗微生物组合物
US20110146671A1 (en) * 2006-12-01 2011-06-23 James Zhou Liu Pharmaceutical compositions and methods of delivering the same
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
WO2008134721A1 (en) * 2007-04-30 2008-11-06 Smithkline Beecham Corporation Methods for administering anti-il-5 antibodies
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
DK2231065T3 (da) 2007-12-18 2021-02-01 Intersect Ent Inc Selvekspanderende anordninger
CN101214221A (zh) * 2007-12-27 2008-07-09 黄明 治疗鼻炎鼻窦炎药物制剂
US9314524B2 (en) * 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
CA2719786A1 (en) 2008-03-28 2009-10-01 Glaxosmithkline Llc Methods of treatment
WO2009146104A1 (en) 2008-04-02 2009-12-03 Accentia Biopharmaceuticals, Inc. Formulations, devices and methods for treating and preventing mucositis
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
CN102014957B (zh) 2008-04-21 2014-12-10 奥德纳米有限公司 用于治疗耳部疾病和病况的耳用调配物
US8030297B2 (en) 2008-05-14 2011-10-04 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
JP5839189B2 (ja) * 2008-07-21 2016-01-06 オトノミ—，インク． 耳の不調の治療用の制御放出性の抗菌性組成物および方法
US8580801B2 (en) * 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
US8763222B2 (en) 2008-08-01 2014-07-01 Intersect Ent, Inc. Methods and devices for crimping self-expanding devices
CN106039547A (zh) 2009-05-15 2016-10-26 因特尔赛克特耳鼻喉公司 可展开装置及其使用方法
WO2011100170A1 (en) * 2010-02-10 2011-08-18 Albert Cha Nasal irrigation systems
US20120003300A1 (en) * 2010-06-30 2012-01-05 Pangaea Laboratories Ltd Composition Comprising Vascular Endothelial Growth Factor (VEGF) for the Treatment of Hair Loss
US9669044B2 (en) 2010-12-14 2017-06-06 Utah State University Aminoglycoside and azole compositions and methods
CN104105472A (zh) * 2011-12-20 2014-10-15 维奥姆生物科学有限公司 用于治疗真菌感染的局部油组合物
SI2852391T1 (sl) 2012-05-21 2022-04-29 Insmed Incorporated Sistemi za obravnavo pljučnih infekcij
JP6529438B2 (ja) 2012-11-29 2019-06-12 インスメッド インコーポレイテッド 安定化されたバンコマイシン処方物
WO2014151963A2 (en) 2013-03-14 2014-09-25 Intersect Ent, Inc. Systems, devices, and method for treating a sinus condition
WO2014186804A2 (en) * 2013-05-17 2014-11-20 Utah State University Aminoglycoside and azole compositions and methods
CN104208701A (zh) * 2013-05-29 2014-12-17 天津金耀集团有限公司 含有抗真菌药物的复方吸入制剂
FR3009622B1 (fr) * 2013-08-09 2015-08-07 Novacyt Procede et dispositif de lavage d'un dispositif de pipetage-distribution
MX2016002408A (es) 2013-08-27 2016-10-28 Otonomy Inc Metodos para el tratamiento de trastornos oticos pediatricos.
CN106233141B (zh) 2014-02-18 2018-08-21 罗伯特·I·汉金 用于诊断和治疗味觉或嗅觉的损失和/或失真的方法和组合物
EP3466432B1 (en) 2014-05-15 2020-07-08 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
BR112017010439B1 (pt) * 2014-11-21 2023-03-07 F2G Limited Composto, composição farmacêutica, combinação farmacêutica, kit, métodos para controle de uma doença fúngica em uma planta, e, uso de um composto, de uma composição ou de uma combinação
CN113679931A (zh) 2015-01-22 2021-11-23 因特尔赛克特耳鼻喉公司 药物涂覆的气囊
US20180071281A1 (en) * 2016-08-19 2018-03-15 Gerbe Labs Inc. Treating chronic rhinosinusitis
EP3512513A4 (en) 2016-09-16 2020-04-15 Otonomy, Inc. GEL FORMULA FOR THE EAR FOR TREATING OTITIS EXTERNA
JP7295038B2 (ja) 2017-06-06 2023-06-20 グラクソスミスクライン エルエルシー 小児患者のための生物薬剤組成物及び方法
EP3768270A4 (en) * 2018-03-19 2021-12-08 Sheo Pharmaceuticals METHODS AND COMPOSITIONS FOR TREATING IDIOPATHIC PULMONARY FIBROSIS
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
CN111249219B (zh) * 2018-11-30 2023-08-11 中南大学湘雅三医院 治疗耳道真菌的滴耳液及其制备方法
AU2020229360A1 (en) * 2019-02-27 2021-08-19 Oticara, Inc. Method for treating nasal, sinonasal, and nasopharyngeal tissue infection and/or inflammation
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
DE2350315C2 (de) * 1973-10-06 1984-01-12 Johnson & Johnson GmbH, 4000 Düsseldorf Pharmazeutische und kosmetische Präparate zur äußerlichen Anwendung
US4209447A (en) 1975-01-27 1980-06-24 Janssen Pharmaceutica N.V. Imidazole derivatives and intermediates in their preparation
US3991750A (en) 1975-04-28 1976-11-16 Syntex Corporation Dromostanolone propionate implant pellet useful for producing weight gains in animals and suppressing estrus in female animals
US4402957A (en) 1979-04-04 1983-09-06 Janssen Pharmaceutica N.V. Heterocyclic derivatives of [4-(piperazin-1-ylphenyloxymethyl)-1,3-dioxolan-2-ylmethyl]-1H-imidazoles and 1H-1,2,4-triazoles
US4334538A (en) 1979-12-12 1982-06-15 Juhn Steven K Aspirator for collecting liquid samples
US4432991A (en) 1981-07-13 1984-02-21 American Cyanamid Company Therapeutically active 3-amino-1-phenyl(and substituted phenyl)-2-pyrazolines
US4883785A (en) * 1984-07-27 1989-11-28 Chow Wing Sun Complex of anti-fungal agent and cyclodextrin and method
US4916134A (en) 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
US5487739A (en) 1987-11-17 1996-01-30 Brown University Research Foundation Implantable therapy systems and methods
US5075309A (en) 1989-06-09 1991-12-24 Janssen Pharmaceutica N.V. Antifungal 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]triazolones and imidazolones
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5310545A (en) * 1991-04-11 1994-05-10 Drore Eisen Method of treatment using mouthwashes containing steroids and antifungal agents and compositions of matter
US5248504A (en) 1992-03-02 1993-09-28 Friedman William H Method of treatment for nasal and sinus dysfunction
ES2170074T3 (es) 1992-09-10 2002-08-01 Childrens Medical Center Matrices de polimero biodegradables para la liberacion prolongada de agentes anestesicos locales.
CA2106034A1 (en) 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
JP3918119B2 (ja) 1993-01-21 2007-05-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 局所用ケトコナゾール組成物
RU2128053C1 (ru) 1993-03-19 1999-03-27 Налепо Лидия Филимоновна Средство для лечения бронхиальной астмы (варианты)
PH31594A (en) 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
US5582167A (en) 1994-03-02 1996-12-10 Thomas Jefferson University Methods and apparatus for reducing tracheal infection using subglottic irrigation, drainage and servoregulation of endotracheal tube cuff pressure
US5952314A (en) * 1994-04-01 1999-09-14 Demichele; Stephen Joseph Nutritional product for a person having ulcerative colitis
EP0771205A2 (de) * 1994-06-28 1997-05-07 Dr. Zerle Gmbh Neue klinische anwendungen von polyen-makroliden
US5599795A (en) * 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
US5658881A (en) 1994-10-14 1997-08-19 Twk, Inc. Method for topical inhibition of the metabolic activity of cytochrome P450
US5679648A (en) * 1994-11-30 1997-10-21 The University Hospital Methods for the treatment and prevention of fungal infections by administration of 3'-deoxypurine nucleosides
US5614206A (en) 1995-03-07 1997-03-25 Wright Medical Technology, Inc. Controlled dissolution pellet containing calcium sulfate
JP3434396B2 (ja) * 1995-06-30 2003-08-04 株式会社日立ユニシアオートモティブ 鼻腔用投薬器
GB9514878D0 (en) 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
DE19541815B4 (de) * 1995-11-09 2008-04-10 Bannert, Christian, Dr. Verwendung einer Lösung von Polyethylenglykol in Wasser als wässrige Spüllösung zur Prävention oder Behandlung von zähem Schleim, der in Verbindung mit Strahlen- oder/und Chemotherapie-induzierten Erkrankungen der Schleimhäute auftritt
US5756127A (en) 1996-10-29 1998-05-26 Wright Medical Technology, Inc. Implantable bioresorbable string of calcium sulfate beads
RU2139707C1 (ru) 1996-12-24 1999-10-20 ОАО Нижегородский химико-фармацевтический завод Суппозитории, обладающие противогрибковым действием (варианты)
PT1024814E (pt) * 1997-10-22 2007-11-29 Mayo Foundation Utilização de agentes antifúngicos para o tratamento tópico de mucosite induzida por fungo
US5897872A (en) 1997-11-12 1999-04-27 Picciano; Dante J. Iodine-containing nasal moisturizing saline solution
EP1051129B1 (en) 1998-01-30 2006-04-05 Wilk Patent Development Corporation Transmyocardial coronary artery bypass and revascularization

Also Published As

Publication number Publication date
US20020052390A1 (en) 2002-05-02
DE69838338D1 (de) 2007-10-11
JP2007008951A (ja) 2007-01-18
TR200001117T2 (tr) 2000-09-21
EP1024814B1 (en) 2007-08-29
US20010002400A1 (en) 2001-05-31
KR20060002015A (ko) 2006-01-06
WO1999020261A3 (en) 2000-02-17
ES2292210T3 (es) 2008-03-01
PT1024814E (pt) 2007-11-29
CA2308201C (en) 2010-09-28
EP1857113A3 (en) 2007-12-19
NO20002069D0 (no) 2000-04-19
IL135774A0 (en) 2001-05-20
CN1282251A (zh) 2001-01-31
US20050124561A1 (en) 2005-06-09
KR100883149B1 (ko) 2009-02-10
US20030153516A1 (en) 2003-08-14
EA200000439A1 (ru) 2000-12-25
JP2006096770A (ja) 2006-04-13
BG104371A (en) 2000-12-29
CA2308201A1 (en) 1999-04-29
IS5463A (is) 2000-04-19
HK1029935A1 (en) 2001-04-20
EP1024814A2 (en) 2000-08-09
IL135774A (en) 2006-08-20
NO20002069L (no) 2000-06-21
CN1143679C (zh) 2004-03-31
US6291500B2 (en) 2001-09-18
ATE371457T1 (de) 2007-09-15
WO1999020261A2 (en) 1999-04-29
NO325714B1 (no) 2008-07-07
EE200000253A (et) 2001-06-15
AU1195999A (en) 1999-05-10
US20010031779A1 (en) 2001-10-18
KR20010031363A (ko) 2001-04-16
SK5732000A3 (en) 2000-10-09
US6207703B1 (en) 2001-03-27
US20010006944A1 (en) 2001-07-05
KR20070069220A (ko) 2007-07-02
HUP0004170A3 (en) 2001-12-28
DE69838338T2 (de) 2008-05-21
US20090253645A1 (en) 2009-10-08
AP2000001805A0 (en) 2000-06-30
US20030091510A1 (en) 2003-05-15
PL340606A1 (en) 2001-02-12
BR9814615A (pt) 2001-10-16
US6555566B2 (en) 2003-04-29
KR20060066753A (ko) 2006-06-16
OA11351A (en) 2003-12-18
DK1024814T3 (da) 2008-01-02
EP1857113A2 (en) 2007-11-21
JP2001520188A (ja) 2001-10-30
ID26104A (id) 2000-11-23

Similar Documents

Publication Publication Date Title
HUP0004170A2 (hu) Eljárás és anyagok nyálkaszövetek gyulladásának kezelésére és megelőzésére
RU94038043A (ru) Применение замещенных производных аденина для лечения множественного склероза
TNSN04113A1 (en) 3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
EP1140170A4 (en) NOVEL AGENTS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF EYE DISORDERS
KR960700742A (ko) 아토피성질환 치료약(atopic disease remedy)
EA200000608A1 (ru) Предотвращение и лечение амилоидогенного заболевания
ATE297204T1 (de) Heilmittel für neurodegenerative krankheiten
EP1390491A4 (en) METHOD OF TREATING NEURODEGENERATIVE, PSYCHIATRIC AND OTHER DISEASES WITH DEACETYLASE INHIBITORS
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
ATE241365T1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
MX9605650A (es) Formulaciones de propionato de fluticasona.
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
ATE207352T1 (de) Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
KR960703009A (ko) 중추유래의 수면성 무호흡증 및 호흡곤란증의 치료를 위한 모다피닐의 사용
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
DK0735877T3 (da) 6-(2-imidazolinylamino)quinoxalinforbindelser, der er egnede som alfa-2-adrenoceptoragonister.
DE60231131D1 (de) Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose
ATE169225T1 (de) Anwendung von urodilatin bei lungen- und bronchialerkrankungen
AU5116298A (en) The use of adamantane amines or structurally similar compounds for combating borna disease virus and for the prevention and treatment of affective diseases and other disorders associated with BDV infections in humans and animals
NO982989L (no) Anvendelse av inhibitorer av den cellulµre Na+/H+-utbytteren (NHE) for fremstilling av et medikament for respiratorstimulering
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
RS8504A (en) Novel cyclohexil sulphones
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
AP1896A (en) The method of treating cancer